Medical Doctor Program year 2022 Reported 2019–2022 Source: CMS Open Payments, 2026 publication

Roxanne Dryden Edwards

Psychiatry Gaithersburg, MD Medical Doctor

NPI 1669429742 CMS profile 166094

9055 Shady Grove Ct, Gaithersburg, MD 20877

Open in the dashboard

General payments

$5,317

258 records reported · program years 2019–2022

Research payments

$0

Paid to them · None reported · program years 2019–2022

Ownership & investment interest

$0

None reported

Through program year 2022, Roxanne Dryden Edwards of Gaithersburg, MD is reported in the CMS Open Payments database as having received $5,317 across 258 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 89th percentile of Psychiatry profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

4 rows
Year Kind Relative to this record's peak year Amount Records
2022 General $52 2
2021 General $1,043 45
2020 General $1,618 86
2019 General $2,604 125

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Roxanne Dryden Edwards
  • Psychiatry median
  • Middle half of Psychiatry
  • National median

In program year 2025, general payments to Roxanne Dryden Edwards were reported at $0. Among 14,155 Psychiatry profiles paid that year, the median was $180 and the middle half received between $58 and $685.

Show as a table
Year Roxanne Dryden Edwards Psychiatry median Middle half National median
2019 $2,604 $184 $59–$605 $163
2020 $1,618 $119 $36–$372 $114
2021 $1,043 $143 $43–$576 $132
2022 $52 $153 $50–$590 $149
2023 $0 $170 $56–$651 $160
2024 $0 $179 $57–$673 $164
2025 $0 $180 $58–$685 $169

Breakdown

Who paid General payments · program years 2019–2022
  1. Otsuka America Pharmaceutical, Inc. $1,123 48 payments
  2. Takeda Pharmaceuticals U.S.A., Inc. $682 39 payments
  3. Supernus Pharmaceuticals, Inc. $659 5 payments
  4. Sunovion Pharmaceuticals Inc. $520 27 payments
  5. Lundbeck LLC $417 20 payments
  6. Arbor Pharmaceuticals, Inc. $357 28 payments
  7. Neurocrine Biosciences, Inc. $235 14 payments
  8. Adlon Therapeutics L.P. $210 10 payments
  9. Vanda Pharmaceuticals Inc. $191 14 payments
  10. Janssen Pharmaceuticals, Inc $153 11 payments
  11. Other $770 42 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2022
  1. Food and Beverage $4,805 253 payments
  2. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $500 1 payment
  3. Education $13 4 payments
Products named General payments · program years 2019–2022
  1. REXULTI $922 40 payments
  2. LATUDA $520 27 payments
  3. TRINTELLIX Neuroscience $483 19 payments
  4. ABILIFY MAINTENA $384 16 payments
  5. Evekeo ODT $282 20 payments
  6. INGREZZA $235 14 payments
  7. ADHANSIA XR $210 10 payments
  8. FANAPT $191 14 payments
  9. HETLIOZ $180 11 payments
  10. Trintellix Central Nervous System (CNS) $177 19 payments
  11. Other $1,570 95 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Records

258 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Psychiatry in Maryland

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2022

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record